Regeneron Pharmaceuticals Sees Institutional Investor Boost

Perpetual Ltd acquires over 2,100 shares of REGN stock in Q4 2025

Apr. 5, 2026 at 9:33am

Got story updates? Submit your updates here. ›

Perpetual Ltd, an institutional investor, bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter of 2025, acquiring 2,145 shares of the biopharmaceutical company's stock valued at approximately $1.66 million. This purchase adds to the growing institutional ownership of Regeneron, which already has 83.31% of its shares held by large investors.

Why it matters

Regeneron Pharmaceuticals is a major player in the biotech industry, known for its innovative drug discovery technologies and pipeline of biologic therapies. Institutional investors like Perpetual Ltd taking significant positions in the stock signals confidence in the company's long-term growth potential and ability to deliver returns for shareholders.

The details

According to a recent SEC filing, Perpetual Ltd bought 2,145 shares of Regeneron Pharmaceuticals in Q4 2025, adding to the company's institutional investor base. This purchase was part of a broader trend, as other large investors such as Aspiriant LLC, Bouchey Financial Group Ltd, and Perigon Wealth Management LLC also took new or increased positions in Regeneron during the same period.

  • Perpetual Ltd acquired the 2,145 shares of Regeneron Pharmaceuticals in Q4 2025.

The players

Perpetual Ltd

An institutional investor that purchased 2,145 shares of Regeneron Pharmaceuticals, Inc. in the fourth quarter of 2025.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Regeneron Pharmaceuticals' growing institutional investor base, including the recent purchase by Perpetual Ltd, signals that major financial players see long-term value in the company's innovative drug pipeline and business model. This trend could help drive continued growth and shareholder returns for Regeneron in the years ahead.